Higher proportions of Treg and proliferating CD8+ T cells were both associated with poor survival in malignancies lung cancer [41], suggesting that DC-CIK immunotherapy may play a role in enhancing the immune function of NSCLC patients. The gene discussed is CD8A; the disease is lung carcinoma.